阿格列汀治疗2型糖尿病合并冠心病的临床效果

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical effect of Alogliptin in the treatment of patients with type 2 diabetes mellitus complicated with coronary heart disease.Methods A total of 80 patients with type 2 diabetes mellitus complicated with coronary heart disease from January 2017 to November 2018 in Department of Endocrinology and Geriatrics of Ganzhou Municipal Hospital were selected as the study subjects, and divided into two groups by computer random method,40 cases in each group.The patients in the observation group were treated with Alogliptin, while those in the control group were treated with routine therapy.The treatment effect, adverse reactions, blood glucose levels before and after treatment, number of angina attacks per week and duration of each angina attack were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group, with statistically significant differences (P＜0.05).After treatment, the levels of fasting blood glucose (FPG), postprandial blood glucose (2 h PG) and glycosylated hemoglobin (HbA1c) in the observation group were lower than those in the control group, with statistically significant differences (P＜0.05).After treatment, the number of angina attacks in the observation group was less than that in the control group, and the duration of each angina attack was shorter than that in the control group, with statistically significant differences (P＜0.05).Conclusion Alogliptin has a good curative effect on patients with type 2 diabetes complicated with coronary heart disease, which can stabilize blood glucose level and guarantee drug safety.It is worth studying.

Key words： Alogliptin Type 2 diabetes mellitus Coronary heart disease Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Chang-dong
	ZENG Xiao-bing
	XIE Bao-qiang
	XIE Fei-fei
	ZHOU Liang

Cite this article:

ZHU Chang-dong,ZENG Xiao-bing,XIE Bao-qiang, et al. Clinical effect of Alogliptin in the treatment of type 2 diabetes mellitus complicated with coronary heart disease[J]. 中国当代医药, 2020, 27(11): 63-66.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I11/63

[1]	张宇宁.强化降糖治疗对老年2型糖尿病合并冠心病血糖、血脂、生存质量、心脏功能的影响[J].中国老年学杂志，2018，38（16）：3860-3862.
[2]	李静芳，张苏河，张东铭，等.2型糖尿病合并冠心病患者的心率变异性及其与心脏结构功能变化的关系[J].山东医药，2017（17）：19-22.
[3]	殷璐，董其娟，于江红.血糖波动对2型糖尿病合并冠心病患者血清对氧磷酶3 和载脂蛋白A1 影响的研究[J].中国糖尿病杂志，2018，26（5）：380-384.
[4]	高速，田雪，姜维娜.中西医结合治疗2型糖尿病合并冠心病的临床疗效及对血清成纤维细胞生长因子-21、Ghrelin 的影响与意义[J].海南医学院学报，2018，24（22）：1954-1958..
[5]	郭洁，张玉，孙耀东.利拉鲁肽联合二甲双胍对2型糖尿病合并冠心病患者血脂水平、心功能的影响[J].中国循证心血管医学杂志，2018，10（10）：1220-1223.
[6]	郭洁，孙耀东，贾万明.利拉鲁肽对2型糖尿病合并冠心病患者血清炎症因子及同型半胱氨酸的影响[J].新疆医科大学学报，2018，41（11）：1347-1350.
[7]	徐泉崧.阿托伐他汀在老年2型糖尿病合并冠心病治疗中的效果观察[J].北方药学，2018，15（2）：107-108.
[8]	陈奇盛，张萍，梁慧.阿托伐他汀钙对中老年2型糖尿病合并冠心病的疗效分析[J].广西医科大学学报，2018，35（6）：858-861.
[9]	宋军，徐会圃.阿托伐他汀钙在治疗2型糖尿病合并冠心病患者中的疗效探究[J].糖尿病天地，2018，15（7）：50.
[10]	夏威，张云，张菱.血清Ghrelin 水平与老年2型糖尿病轻度认知障碍的关系研究[J].中华神经医学杂志，2018，17（8）：831-834.
[11]	严恒.不同剂量美托洛尔治疗2型糖尿病合并冠心病的临床疗效评价[J].糖尿病新世界，2018，21（9）：82-84.
[12]	吕俊芳.化浊通痹汤治疗2型糖尿病合并冠心病45例[J].河南医学高等专科学校学报，2018，30（2）：152-154.
[13]	袁国良.强化降糖治疗对2型糖尿病合并冠心病患者不良心血管事件的影响[J].糖尿病天地，2018，15（12）：154-155.
[14]	曹英杰.利拉鲁肽联合二甲双胍治疗2型糖尿病合并冠心病的效果观察[J].糖尿病新世界，2018，21（7）：59-60.
[15]	Kusamori K，Nishikawa M，Mizuno N，et al.Transplantation of insulin-secreting multicellular spheroids for the treatment of type 1 diabetes in mice[J].J Control Release，2014，173：119-124.
[16]	Colmegna P，Sánchez Pena RS.Analysis of three T1DM simulation models for evaluating robust closed-loop controllers[J].Comput Method Program Biomed，2014，113（1）：371-382.
[17]	Lo J，Ljubicic S，Leibiger B，et al.Adipsin is an Adipokine that improves β cell function in diabetes[J].Cell，2014，158（1）：41-53.
[18]	Skrivarhaug T，Stene LC，Drivvoll AK，et al.Incidence of type 1 diabetes in Norway among children aged 0-14 years between 1989 and 2012：Has the incidence stopped rising results from the norwegian childhood diabetes registry[J].Diabetologia，2014，57（1）：57-62.
[19]	罗小雨，廖湘竹，李莉.妊娠期糖尿病患者血清同型半胱氨酸、胱抑素C 及尿酸检测的临床价值[J].现代医院，2018，18（4）：616-617.
[20]	Holden SE，Bannister CA，Currie CJ.Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment：(questionable) classification of diabetic patients based on combination of specific glucoselowering drugs[J].Diabetologia，2014，57（9）：2001-2002.
[21]	陶磊，高伟，刘怡等.系统评价阿格列汀治疗2型糖尿病的有效性和安全性[J].海峡药学，2018，30（12）：184-185.